ArticleCell communication and signaling : CCS2026
C-terminal tail of MAVS dictates organelle targeting and innate immune response.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMAVS is a mitochondrial and peroxisomal protein that adapts innate RNA sensing by RIG-I-like receptors to downstream signalling. MAVS aggregation is required for the propagation of the activation signal, however whether this requirement varies with respect to subcellular localization remains unclear.
methodsMAVS mutants were expressed in transfected, lentivirus-transduced and Sendai virus-infected cells. They were then analysed for subcellular localization by confocal immunofluorescence microscopy, for aggregation by semi-denaturing gel electrophoresis, and for activation of type I interferon production by Western blotting of phosphorylated IRF3 and ELISA of interferon β.
resultsWe identified that MAVS aggregation is required for innate immune signalling triggered by mitochondrial but not peroxisomal MAVS. An aggregation-deficient mutant of peroxisomal MAVS retained its ability to induce type I interferon production. We further demonstrated that the magnitude of the activation signal and the distribution of MAVS to mitochondria and peroxisomes are governed by the tail charge at the C-terminus of MAVS. An increase in tail charge directs MAVS to peroxisomes predominantly, leading to a more modest activation of innate immune signalling.
conclusionThese results suggest that MAVS displays compartment-specific properties that are mechanistically and functionally distinct in RNA sensing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.